Shell Asset Management Co. lessened its holdings in shares of Humana Inc (NYSE:HUM) by 6.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,854 shares of the insurance provider’s stock after selling 1,358 shares during the period. Shell Asset Management Co.’s holdings in Humana were worth $6,235,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Northwestern Mutual Investment Management Company LLC raised its holdings in shares of Humana by 34.2% during the first quarter. Northwestern Mutual Investment Management Company LLC now owns 6,904 shares of the insurance provider’s stock valued at $2,168,000 after buying an additional 1,760 shares during the last quarter. AGF Investments Inc. bought a new stake in Humana during the first quarter worth approximately $906,000. United Asset Strategies Inc. bought a new stake in Humana during the first quarter worth approximately $421,000. Nvwm LLC raised its holdings in Humana by 2.2% during the first quarter. Nvwm LLC now owns 2,583 shares of the insurance provider’s stock worth $813,000 after purchasing an additional 56 shares in the last quarter. Finally, Commerce Bank raised its holdings in Humana by 9.9% during the first quarter. Commerce Bank now owns 5,769 shares of the insurance provider’s stock worth $1,812,000 after purchasing an additional 522 shares in the last quarter. 93.22% of the stock is currently owned by institutional investors.
NYSE HUM traded down $0.84 on Friday, hitting $394.43. 415,854 shares of the stock were exchanged, compared to its average volume of 962,079. Humana Inc has a 52-week low of $208.25 and a 52-week high of $412.70. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.66 and a quick ratio of 1.66. The company has a market capitalization of $52.26 billion, a price-to-earnings ratio of 20.25, a P/E/G ratio of 1.73 and a beta of 0.91. The company’s 50-day moving average price is $361.93 and its two-hundred day moving average price is $345.82.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share for the quarter, topping the consensus estimate of $4.84 by $0.56. Humana had a net margin of 3.86% and a return on equity of 21.02%. The firm had revenue of $18.94 billion for the quarter, compared to analysts’ expectations of $18.49 billion. During the same period in the previous year, the company posted $4.48 EPS. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. Equities analysts predict that Humana Inc will post 18.55 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.625 per share. This represents a $2.50 annualized dividend and a dividend yield of 0.63%. The ex-dividend date is Monday, June 29th. Humana’s dividend payout ratio is currently 13.99%.
In other news, Director David A. Jr/Ky Jones sold 5,800 shares of the business’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $256.19, for a total transaction of $1,485,902.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.42% of the company’s stock.
Several brokerages recently commented on HUM. Deutsche Bank boosted their target price on Humana from $363.00 to $433.00 and gave the stock a “hold” rating in a report on Tuesday, February 18th. Cantor Fitzgerald boosted their target price on Humana from $345.00 to $400.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Royal Bank of Canada reissued a “hold” rating and set a $370.00 target price on shares of Humana in a report on Wednesday, February 19th. SunTrust Banks boosted their target price on Humana from $400.00 to $440.00 and gave the stock a “hold” rating in a report on Thursday. Finally, Oppenheimer boosted their target price on Humana from $400.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, April 30th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $405.42.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: Producer Price Index (PPI)
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.